Spherix Announces New Agreements to Develop and Market D-tagatose

Spherix Announces New Agreements to Develop and Market D-tagatose 
TYSONS CORNER, VA -- (Marketwired) -- 05/02/13 --   Spherix
Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for
therapy in diabetes, metabolic syndrome and atherosclerosis, today
announced the signing of a memorandum of understanding (MOU) with
ChromaDex (OTCQB: CDXC) to extend the commercial market for
D-tagatose, extend the structure function claims for the GRAS food
ingredient, and to optimize a new system of D-tagatose production. 
D-tagatose is a natural sweetener present in only small amounts in
fruits and dairy products, but it can be commercially produced
through an enzymatic process beginning with other natural sugars.
With the same bulk and sweetness of regular sugar (i.e., sucrose) and
no after-taste, D-tagatose is an ideal solution for sweet and savory
products. D-tagatose has a documented prebiotic effect and a low
caloric value of 1.5 kcal per gram. D-tagatose has a glycemic and
insulin index of only 3% of that of glucose.  
The market for D-tagatose has begun to grow. Late last year, Spherix
announced the signing of an agreement granting Fullife in India an
exclusive, royalty bearing license for the use of Spherix's clinical
data and proprietary knowledge to support the marketing and dosing of
D-tagatose that Spherix is now supplying. In new developments in
other markets, Bio Foods in Chile has exchanged a nonbinding term
sheet with Spherix for D-tagatose in the Chilean territory. More
recently, Spherix signed a nondisclosure agreement with WIO
SmartFoods LLC in Utah and began selling D-tagatose to that company
for use in its WIO SmartFoods product line (shipments have already
been delivered). WIO certifies bariatric clinics and diet clinics to
use its proprietary meal replacement plan to promote weight loss. WIO
focuses on helping people with the metabolic syndrome, which is
characterized by obesity, diabetes, and atherosclerosis. Expanding
the structure function claims for D-tagatose make it more valuable
than a simple artificial sweetener. The market for tagatose in both
the USA and abroad appears poised to grow. 
The biggest problem with widespread adoption of tagatose to date has
been the cost of production, which has limited supplies. ChromaDex
has agre
ed in the recently signed a memorandum of understanding to
work with Spherix to evaluate the supply chain and optimize a more
efficient scalable process for the production of tagatose. Troy
Rhonemus, Director of New Technologies and Supply Chain Development,
who will lead the project for ChromaDex, brings 14 years of
experience in business, operations, and R&D management to the task. 
"Consumers continue to look for products that help manage calories in
the foods and beverages they consume," stated Mr. Rhonemus.
"Developing a product that tastes great and enables the consumer to
manage their caloric intake would be the 'Holy Grail' of the
sweetener industry. If such a product was developed that could be
manufactured cost effectively and be sustainable this would
revolutionize the sweetener industry."  
Mr. Rhonemus was previously the product line lead manager at Cargill
Health and Nutrition responsible for managing the operations and
supply chain of the Truvia(R) brand stevia sweetener with a focus on
technology, agronomy, and sustainability. ChromaDex has a right of
first refusal for marketing and selling the new D-tagatose in the
signed MOU. 
About Spherix
 Spherix offers a new fully diversified, global
commercialization platform for patent protected technologies. Spherix
is committed to advancing innovation by active participation in all
areas of the patent market. Spherix draws on portfolios of pioneering
technology patents to partner with and support product innovation.
Through its recently announced acquisition of several hundred patents
issued to Harris Corporation expected to close later this year,
Spherix intends to expand its activities in wireless communications
and telecommunication sectors including antenna technology, Wi-Fi,
base station functionality, and cellular. Spherix Incorporated was
launched in 1967 as a scientific research company under the name
Biospherics Research. The Biospherics division continues to be
dedicated to developing and licensing/marketing proprietary drugs and
therapeutic products for treatment of diabetes, metabolic syndrome
and atherosclerosis and has several patent applications pending. For
more information, please visit www.spherix.com. 
About ChromaDex(R): 
 ChromaDex(R) is an innovative natural products
company that discovers, acquires, develops and commercializes
proprietary-based ingredient technologies through its unique business
model which utilizes its wholly-owned synergistic business units,
including ingredient technologies, natural product fine chemicals
(known as "phytochemicals"), chemistry and analytical testing
services, and product regulatory and safety consulting (as Spherix
Consulting). The Company provides seamless science-based solutions to
the dietary supplement, food & beverage, animal health, cosmetic and
pharmaceutical industries. Our ingredient technologies unit includes
products backed with extensive scientific research and intellectual
property. The ingredient portfolio includes pTeroPure(R)
pterostilbene; ProC3G(TM), a natural black rice containing
cyanidine-3-glucoside; PURENERGY(TM), a caffeine-pTeroPure
co-crystal; nutraGac(TM), a gac fruit powder; curcumin, and
nicotinamide riboside, a novel next-generation B-vitamin currently
under development. To learn more about ChromaDex please visit
Forward-Looking Statements
 This release contains forward-looking
statements which are made pursuant to provisions of Section 21E of
the Securities Exchange Act of 1934. Investors are cautioned that
such statements in this release, including statements relating to
planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for
existing or proposed products, constitute forward-looking statements
which involve risks and uncertainties that could cause actual results
to differ materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without limitation,
risks that product candidates may fail in the clinic or may not be
successfully marketed or manufactured, we may lack financial
resources to complete development of our products, the FDA may
interpret the results of studies differently than us, competing
products may be more successful, demand for new pharmaceutical
products may decrease, the biopharmaceutical industry may experience
negative market trends, our continuing efforts to develop products
may be unsuccessful, our common stock could be delisted from the
Nasdaq Capital Market, and other risks and challenges detailed in our
filings with the U.S. Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on any forward-looking
statements which speak only as of the date of this release. We
undertake no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events. 
Spherix Incorporated
Investor Relations 
Phone: (301) 897-2564
Email: info@spherix.com 
Press spacebar to pause and continue. Press esc to stop.